These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28146132)

  • 21. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
    Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
    Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
    Uusitalo H; Pillunat LE; Ropo A;
    Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety.
    Kuwayama Y; Nomura A
    Adv Ther; 2014 Apr; 31(4):461-71. PubMed ID: 24615289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy.
    Miki T; Naito T; Fujiwara M; Araki R; Kiyoi R; Shiode Y; Fujiwara A; Morizane Y; Shiraga F
    PLoS One; 2017; 12(7):e0181550. PubMed ID: 28727804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
    Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
    Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
    Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence.
    Kuwayama Y; Hashimoto M; Kakegawa R; Nomura A; Shimada F
    Adv Ther; 2017 Jun; 34(6):1411-1425. PubMed ID: 28502035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma.
    Lorenz K; Pfeiffer N
    Expert Opin Pharmacother; 2014 Oct; 15(15):2255-62. PubMed ID: 25170534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.
    Takagi Y; Nakajima T; Shimazaki A; Kageyama M; Matsugi T; Matsumura Y; Gabelt BT; Kaufman PL; Hara H
    Exp Eye Res; 2004 Apr; 78(4):767-76. PubMed ID: 15037111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of repeated administrations of tafluprost, latanoprost, and travoprost on optic nerve head blood flow in conscious normal rabbits.
    Akaishi T; Kurashima H; Odani-Kawabata N; Ishida N; Nakamura M
    J Ocul Pharmacol Ther; 2010 Apr; 26(2):181-6. PubMed ID: 20334534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The circadian changes of intraocular pressure and ocular perfusion pressure after tafluprost compared with travoprost in normal tension glaucoma.
    Shin J; Lee JW; Choi BS; Yun EY; Jung JH; Kim EA; Caprioli J
    J Ocul Pharmacol Ther; 2014 Dec; 30(10):803-9. PubMed ID: 25285367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs.
    Schwartz GF; Tan J; Kotak S
    J Ocul Pharmacol Ther; 2009 Dec; 25(6):555-61. PubMed ID: 20028264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of prostaglandin analogs on blood flow velocity and resistance in the ophthalmic artery of rabbits.
    Giannico AT; Lima L; Shaw GC; Russ HH; Froes TR; Montiani-Ferreira F
    Arq Bras Oftalmol; 2016 Feb; 79(1):33-6. PubMed ID: 26840164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tafluprost, a new potent prostanoid receptor agonist: a dose-response study on pharmacodynamics and tolerability in healthy volunteers.
    Sutton A; Gouws P; Ropo A
    Int J Clin Pharmacol Ther; 2008 Aug; 46(8):400-6. PubMed ID: 18793581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
    Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
    J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma.
    Konstas AG; Holló G
    Expert Opin Pharmacother; 2016 Jun; 17(9):1271-83. PubMed ID: 27123557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor.
    Sharif NA; Kelly CR; Crider JY
    J Ocul Pharmacol Ther; 2002 Aug; 18(4):313-24. PubMed ID: 12222762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 1-year randomized study of the clinical and confocal effects of tafluprost and latanoprost in newly diagnosed glaucoma patients.
    Fogagnolo P; Dipinto A; Vanzulli E; Maggiolo E; De Cilla' S; Autelitano A; Rossetti L
    Adv Ther; 2015 Apr; 32(4):356-69. PubMed ID: 25893514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats.
    Fukano Y; Kawazu K
    Drug Metab Dispos; 2009 Aug; 37(8):1622-34. PubMed ID: 19477946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.